Clinical Trials

Trial Name Description
Keynote 564 Renal Dr. E. Winquist
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy
Checkmate 901 GU Dr. E. Winquist
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
PCS 6 Dr. D'Souza
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI).
Keynote 361 GU Dr. K. Potvin
A Phase III randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
IND.232 GU Dr. E. Winquist
A Phase II Study of Durvalumab (MEDI4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer
MISTER Dr. Eric Winquist
Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer.
PICs GU Dr. G. Bauman
Advanced Prostate Imaging of Recurrent Cancer after Radiotherapy
CEC-CTC Renal Dr. A. Allan
Prospective validation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) as prognostic biomarkers in clear cell renal cancer
CLEAR Dr. Eric Winquist
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carci
NRG GU003 Dr. Glenn Bauman
"not yet open" A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT)Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT).
Javelin Renal 101 Dr. K. Potvin
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta) versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carc
REC.3 Dr. Kylea Potvin
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantanib [NSC#761968], Crizotinib [NSC#749005], Savolitinib [NSC#785348], and Sunitinib [NSC#736511])in Metastatic Papillary Renal Carcinoma (PAPMET).
IMVigor 010 GU Dr. E. Winquist
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy (WO29636)
ATLAS GU Dr. D DSouza
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
AGS 15-3 Renal Dr. S. Ernst
A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
PACE GU Dr. G. Rodrigues
International Randomized Study of Laparoscopic Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Early Stage Organ-Confined Prostate Cancer
Renal mTor Dr. M. Haeryfar
Regulation of T cell responses by inhibitors of mammalian target of rapamycin (mTOR)
FASTR 2 GU Dr. B. Bauman
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer
OZM-053 GU Dr. Belal Ahmad
A Phase II, Multi-Centre Study of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
Keynote 057 GU Dr. E. Winquist
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
TRITON 2 Dr. Scott Ernst
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
TRITON 3 Dr. Scott Ernst
"not yet open" A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency.

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada